Flare Therapeutics Email Format

Biotechnology ResearchMassachusetts, United States51-200 Employees

Flare Therapeutics is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing precision medicines for oncology and other therapeutic areas. It aims to drug transcription factors, a previously undruggable target class, using an integrated discovery platform to identify validated ligands for the undrugged proteome. Its lead program, FX-909, is an oral, first-in-class inhibitor of PPARG for locally advanced or metastatic urothelial cancer, with clinical proof-of-concept in early trials and ongoing Phase 1B dosing. 

Its FX-111 program is a novel degrader targeting ARON, the transcriptionally active, hormone-bound androgen receptor. In 2026, Flare Therapeutics announced it would present three posters at the AACR Annual Meeting 2026, reflecting ongoing clinical activity.

Sign up for free to view info

Company overview Employee directory